A review of avelumab in locally advanced and metastatic bladder cancer
Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287218823485 |